Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Juichi Takada"'
Autor:
Shigehiro Kokubu, Haruki Uojima, Tomoyoshi Inoue, Wasaburo Koizumi, Hisashi Hidaka, Takahide Nakazawa, Juichi Takada, Akitaka Shibuya, Keiji Matsunaga, Keiko Yamane, Kousuke Kubota, Yusuke Okuwaki, Yoshiaki Tanaka
Publikováno v:
Hepatology Research. 47:1118-1126
Aim To examine whether superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance imaging (MRI) can be used to assess the malignant potential of hepatic hypovascular nodules showing hypointensity during the hepatobiliary phase (HBP) on gadoxetic
Autor:
Juichi Takada1 jui-tkd@kitasato-u.ac.jp, Hisashi Hidaka1, Takahide Nakazawa1, Masaaki Kondo2, Kazushi Numata2, Katsuaki Tanaka2, Kotaro Matsunaga3, Chiaki Okuse3, Satoshi Kobayashi4, Manabu Morimoto4, Shinichi Ohkawa4, Wasaburo Koizumi1
Publikováno v:
BMC Research Notes. 10/26/2015, Vol. 8, p1-10. 10p. 1 Diagram, 3 Charts, 5 Graphs.
Autor:
Hisashi Hidaka, Yusuke Okuwaki, Keiko Yamane, Yasuhiro Matsumoto, Kousuke Kubota, Tomoyoshi Inoue, Juichi Takada, Keiji Matsunaga, Tsutomu Minamino, Wasaburo Koizumi, Yoshiaki Tanaka, Takahide Nakazawa, Akitaka Shibuya
Publikováno v:
Hepatology Research. 46:559-564
Aim Portopulmonary venous anastomoses (PPVA) are shunts between esophageal varices and pulmonary veins. Because PPVA can cause serious complications at the time of sclerotherapy for esophageal varices, it is essential to confirm the existence of any
Autor:
Michiko Yanagihara, Hisashi Hidaka, Tsutomu Minamino, Juichi Takada, Takahide Nakazawa, Yusuke Okuwaki, Yoshiaki Tanaka, Wasaburo Koizumi, Akitaka Shibuya, Shigeru Fujii
Publikováno v:
Hepatology Research. 45:976-985
Aim Early evaluation of the response to sorafenib for patients with hepatocellular carcinoma (HCC) remains unclear. This prospective study investigated the early evaluation of the efficacy of sorafenib in patients with advanced HCC using duplex Doppl
Autor:
Yusuke Okuwaki, Tomoyoshi Inoue, Juichi Takada, Kaoru Fujii, Takahide Nakazawa, Reiko Woodhams, Shigehiro Kokubu, Kousuke Kubota, Yoshiaki Tanaka, Haruki Uojima, Akitaka Shibuya, Wasaburo Koizumi, Keiko Yamane, Hisashi Hidaka, Keiji Matsunaga
Publikováno v:
Hepatology Research. 48
Aim Transcatheter arterial chemoembolization (TACE) has been recognized as a treatment option for patients with intermediate hepatocellular carcinoma (HCC). This randomized, controlled study compared the local control efficacy of TACE with miriplatin
Autor:
Masaaki Watanabe, Shigehiro Kokubu, Wasaburo Koizumi, Shouko Komori, Kazushige Hayakawa, Tsutomu Minamino, Hajime Yamamoto, Juichi Takada, Yusuke Okuwaki, Yoshiaki Tanaka, Hisashi Hidaka, Akitaka Shibuya, Takahide Nakazawa
Publikováno v:
Journal of Gastroenterology and Hepatology. 29:352-357
Background and Aim To examine the efficacy and outcomes of radiotherapy (RT) in patients who have hepatocellular carcinoma with invasion to intrahepatic large vessels (IHLVs). Methods Sixty-seven patients who had advanced hepatocellular carcinoma wit
Autor:
Wasaburo Koizumi, Akitaka Shibuya, Hisashi Hidaka, Masaaki Watanabe, Takahide Nakazawa, Shigehiro Kokubu, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino
Publikováno v:
European Journal of Gastroenterology & Hepatology. 25:683-689
To determine the value of early alterations of the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib.Tumor response, over
Autor:
Yoshiaki Tanaka, Yasuhiro Matsumoto, Takahide Nakazawa, Yusuke Okuwaki, Wasaburo Koizumi, Akitaka Shibuya, Makoto Ohbu, Juichi Takada, Tsutomu Minamino, Masaaki Watanabe, Hisashi Hidaka
Publikováno v:
Open Journal of Gastroenterology. :128-133
Aim: We evaluated the long-term effects of olmesartan, an angiotensin type 1 receptor blocker, in patients with non-alcoholic steatohepatitis (NASH) complicated with hypertension. Methods: All patients were given a standard calorie diet and exercise
Autor:
Hisashi Hidaka, Akitaka Shibuya, Juichi Takada, Wasaburo Koizumi, Toru Kaneko, Tsutomu Minamino, Takahide Nakazawa, Masaaki Watanabe, Yoshiaki Tanaka, Yusuke Okuwaki
Publikováno v:
Journal of Gastroenterology. 47:1030-1035
Sorafenib is currently in clinical use as an oral multikinase inhibitor that blocks tumor growth and cell proliferation in advanced hepatocellular carcinoma (HCC). It has been demonstrated in a translating study that sorafenib had a beneficial effect
Autor:
Katsuaki Tanaka, Satoshi Morita, Hisashi Hidaka, Shinichi Ohkawa, Satoshi Kobayashi, Juichi Takada, Manabu Morimoto, Kazushi Numata, Masaaki Kondo, Chiaki Okuse, Masataka Taguri, Akitaka Shibuya
Publikováno v:
Hepatology Research. 41:296-302
Aim: Sorafenib is approved for the treatment of advanced hepatocellular carcinoma (HCC) in Japan; however, its tolerability and efficacy in elderly patients with HCC have not been clarified. We aimed to evaluate the tolerability and efficacy of soraf